News & Events

Clinigen Group Signs Distribution Agreement with MSD UK for Clinical Trial Supply Services

Clinigen Group Signs Distribution Agreement with MSD UK for Clinical Trial Supply Services

MSD Products Further Strengthen Clinigen’s Clinical Trial Supply Services

Burton-on-Trent, UK – 27 February 2015 – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN) today announces that its Clinical Trials Supply business (Clinigen CTS) has entered into an agreement with Merck Sharp & Dohme Limited (‘MSD’), to distribute their human health products for use in clinical trials carried out in Europe. This agreement now represents the fourth arrangement Clinigen CTS has with manufacturers to distribute products.

Under the terms of the agreement, Clinigen CTS will be a preferred distributor and manage enquiries, order receipts and distribution of MSD’s products to manufacturers, contract research organizations (CROs), clinical trial contract packagers and other specialist service providers looking to source pharmaceutical products as comparators, rescue and adjunctive drugs for use in clinical trials.

Steve Glass, Senior Vice President Clinigen CTS said: “The addition of this agreement further strengthens our position within the clinical trial supply market as we continue on our path to become the no.1 global clinical trial supply service provider.”

Notes To Editors

About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering ‘the right drug, to the right patient at the right time’, has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen CTS sources commercial medical products for use in clinical studies only. These include comparator drugs, where existing medical treatments are used as benchmarks to assess the effectiveness of investigative products, adjuvant drugs, which improve the effectiveness of the product being trialed, and rescue therapies, which help patients who have experienced a worsening of symptoms or insufficient therapeutic benefit during a trial.
For more information, please visit

Issued for and on behalf of Clinigen Group by Instinctif Partners.

For more information please contact

back to news


Melanie Toyne-SewellManaging Partner